Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease

Melanoma and Skin Cancer

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Melanoma Res.

Kosche C, Stout M, Sosman J, Lukas RV, Choi JN

doi: 10.1097/CMR.0000000000000642.

Melanoma and Skin Cancer

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

BMC Cancer.

Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T

doi: 10.1186/s12885-017-3785-4.

Melanoma and Skin Cancer

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

Melanoma Res.

Plaquevent M, Greliak A, Pinard C, Duval-Modeste AB, Joly P

doi: 10.1097/CMR.

Melanoma and Skin CancerVitiligo

Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

JAMA Dermatol

Nakamura Y, Teramoto Y, Asami Y, Matsuya T, Adachi JI, Nishikawa R, Yamamoto A

doi: 10.1001/

Melanoma and Skin Cancer

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

J Immunother.

Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, Gogas H

Melanoma and Skin Cancer

Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient

Br J Dermatol.

Gambichler T, Susok L, Fels M, Schneider-Gold C, Hof Zum Berge F, Stockfleth E, Ayzenberg I

doi: 10.1111/bjd.18358.

Melanoma and Skin Cancer

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Melanoma Res.

Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C

doi: 10.1097/CMR.0000000000000703.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Melanoma Res.

Thummalapalli R, Melms JC, Mier J, Izar B

doi: 10.1097/CMR.0000000000000646.

Melanoma and Skin Cancer

Multiple primary melanoma with the Meyerson phenomenon in a young patient

Melanoma Res.

Fernández-Sartorio C, Alós L, García-Herrera A, Ferrando J, Carrera C

doi: 10.1097/

Related content

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Multiple primary melanoma with the Meyerson phenomenon in a young patient